Entera Bio (NASDAQ:ENTX) Stock Price Up 5.1% – Here’s Why

Entera Bio Ltd. (NASDAQ:ENTX) was up 5.1% on Thursday . The stock traded as high as $3.24 and last traded at $3.27. Approximately 89,894 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,130,988 shares. The stock had previously closed at $3.11.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ENTX. Wall Street Zen upgraded Entera Bio to a “sell” rating in a research note on Saturday, August 8th. HC Wainwright restated a “buy” rating on shares of Entera Bio in a report on Wednesday, June 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Entera Bio in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $9.00.

Entera Bio Stock Performance

The business has a 50 day moving average price of $2.12 and a two-hundred day moving average price of $1.57. The stock has a market cap of $559.24 million, a PE ratio of -9.23 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX) last released its earnings results on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06). As a group, research analysts anticipate that Entera Bio Ltd. will post -0.34 earnings per share for the current year.

Institutional Investors Weigh In On Entera Bio

Several large investors have recently made changes to their positions in the business. Seven Fleet Capital Management LP boosted its holdings in shares of Entera Bio by 51.9% in the 1st quarter. Seven Fleet Capital Management LP now owns 205,542 shares of the company’s stock worth $228,000 after buying an additional 70,224 shares during the last quarter. Renaissance Technologies LLC increased its holdings in Entera Bio by 338.4% during the first quarter. Renaissance Technologies LLC now owns 473,442 shares of the company’s stock worth $526,000 after buying an additional 365,441 shares during the last quarter. Superstring Capital Management LP bought a new stake in Entera Bio in the fourth quarter worth about $33,000. Schonfeld Strategic Advisors LLC raised its position in Entera Bio by 5.2% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 596,585 shares of the company’s stock worth $1,157,000 after acquiring an additional 29,629 shares during the period. Finally, Jane Street Group LLC raised its position in Entera Bio by 142.6% in the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after acquiring an additional 43,536 shares during the period. 14.11% of the stock is owned by hedge funds and other institutional investors.

About Entera Bio

Entera Bio, Inc is a clinical?stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.